Access comprehensive financial analyses and make smarter investments - get the Manual of Investments on Amazon!

Integer Holdings Announces Conversion Period for 2.125% Convertible Senior Notes

Integer Holdings Corporation (NYSE: ITGR) has announced the conversion period for its 2.125% Convertible Senior Notes due 2028. The notes are convertible beginning on July 1, 2025, and ending on September 30, 2025. The conversion rate is 11.4681 shares of common stock per $1,000 principal amount of Notes, equivalent to a conversion price of approximately $87.20 per share of common stock. The last reported sale price of shares of the company’s common stock, for at least 20 trading days during the period of 30 consecutive trading days ending on, and including, the last trading day of the calendar quarter ended June 30, 2025, was greater than 130% of the conversion price in effect on each applicable trading day.

Integer Holdings Corporation is a leading medical device contract development and manufacturing organization, serving the cardiac rhythm management, neuromodulation, and cardio and vascular markets. The company's brands include Greatbatch Medical® and Lake Region Medical®.

In the previous period, the conversion rate for the 2.125% Convertible Senior Notes due 2028 was 10.8279 shares of common stock per $1,000 principal amount of Notes, equivalent to a conversion price of approximately $92.34 per share of common stock. This represents a significant change in the conversion rate and conversion price since the last period, indicating potential shifts in the company's stock performance and investor sentiment.

For additional information on Integer Holdings Corporation, interested parties can visit www.integer.net. Following these announcements, the company's shares moved -0.08%, and are now trading at a price of $121.19. If you want to know more, read the company's complete 8-K report here.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.

IN FOCUS